Salud financiera de hoja de balance de BioNTech
Salud financiera controles de criterios 6/6
BioNTech tiene un patrimonio de accionistas total de €20.2B y una deuda total de €2.4M, lo que sitúa su ratio deuda-patrimonio en 0.01%. Sus activos y pasivos totales son €23.0B y €2.8B respectivamente. El BAIT de BioNTech es de €969.6M, por lo que su ratio de cobertura de intereses es de -2.7. Tiene efectivo e inversiones a corto plazo que ascienden a €16.5B.
Información clave
0.01%
Ratio deuda-patrimonio
€2.40m
Deuda
| Ratio de cobertura de intereses | -2.7x |
| Efectivo | €16.55b |
| Patrimonio | €20.25b |
| Total pasivo | €2.76b |
| Activos totales | €23.01b |
Actualizaciones recientes sobre salud financiera
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly
Nov 09Recent updates
BioNTech Earnings Preview: I Will Stay On The Sidelines
May 03BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
Mar 27BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 24BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
Mar 20BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
Feb 23BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate
Feb 09Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%
Jan 18Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price
Jan 02BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook
Oct 22BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)
May 23BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates
Mar 29These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)
Feb 18Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates
Feb 02With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case
Jan 26BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%
Nov 19BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly
Nov 09CDC advisory panel recommends COVID vaccines for children be included in federal program
Oct 19Do BioNTech's (NASDAQ:BNTX) Earnings Warrant Your Attention?
Oct 18Hong Kong approves BioNTech COVID vaccine for infants
Oct 12EMA starts rolling review of Pfizer/BioNTech's Omicron-subvariant adapted shot for kids
Oct 03BioNTech: A Tale Of 2 Companies
Sep 20European drug regulator panel backs approval of Pfizer/BioNTech's Omicron-adapted shot
Sep 12CDC advisors to vote on COVID Omicron vaccines on Sept. 1
Aug 30Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (€19.5B) de BNTX superan a sus pasivos a corto plazo (€2.1B).
Pasivo a largo plazo: Los activos a corto plazo de BNTX (€19.5B) superan a sus pasivos a largo plazo (€689.9M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: BNTX tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de BNTX ha pasado de 2.1% a 0.01% en los últimos 5 años.
Cobertura de la deuda: La deuda de BNTX está bien cubierta por el flujo de caja operativo (223808.3%).
Cobertura de intereses: BNTX gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.